Understanding sarcoma: from diagnosis to treatment
A cancer diagnosis can be scary and confusing, especially for a patient receiving a sarcoma diagnosis.
What is sarcoma?
Sarcoma is a rare cancer of the soft tissues and bone.
Most types of cancer originate in the epithelial linings that cover exposed surfaces of the body and have direct exposure to environmental toxins. Sarcomas, however, originate from cells or tissues that lie below these lini ngs in the muscle, bone, cartilage, fat, blood vessels, smooth muscle and skeletal muscles. Any type… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - June 30, 2019 Category: Biotechnology Authors: Dr. Kamal Ummed Source Type: news
Understanding sarcoma: from diagnosis to treatment
A cancer diagnosis can be scary and confusing, especially for a patient receiving a sarcoma diagnosis.
What is sarcoma?
Sarcoma is a rare cancer of the soft tissues and bone.
Most types of cancer originate in the epithelial linings that cover exposed surfaces of the body and have direct exposure to environmental toxins. Sarcomas, however, originate from cells or tissues that lie below these lini ngs in the muscle, bone, cartilage, fat, blood vessels, smooth muscle and skeletal muscles. Any type… (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - June 30, 2019 Category: Pharmaceuticals Authors: Dr. Kamal Ummed Source Type: news
Mesothelioma Treatment Guidelines Not Followed Often Enough
Too many patients with pleural mesothelioma are going without treatment recommended by National Comprehensive Cancer Network guidelines, according to a recent study at Cedars-Sinai Medical Center in Los Angeles.
Valuable survival time is being lost.
The Annals of Thoracic Surgery published the study that looked at disparities in compliance with national treatment guidelines and their impact on overall survival.
The National Comprehensive Cancer Network, along with the American Society of Clinical Oncology, recommends multimodal therapy — surgery, chemotherapy and possibly radiation therapy — for mesothelioma patients w...
Source: Asbestos and Mesothelioma News - June 12, 2019 Category: Environmental Health Authors: Matt Mauney Source Type: news
Nintedanib Worsens Outcomes Along With Chemo in Advanced Ovarian Cancer
A phase II trial showed that the addition of nintedanib to neoadjuvant chemotherapy did not benefit patients with advanced epithelial ovarian cancer. (Source: CancerNetwork)
Source: CancerNetwork - June 11, 2019 Category: Cancer & Oncology Authors: Dave Levitan Source Type: news
Does Maintenance Rucaparib Improve Post-Progression Outcomes in Ovarian Cancer?
Researchers tested maintenance therapy with rucaparib in a phase III trial of patients with recurrent epithelial ovarian cancer who experienced response to platinum-based chemotherapy. (Source: CancerNetwork)
Source: CancerNetwork - June 10, 2019 Category: Cancer & Oncology Authors: Dave Levitan Source Type: news
Benefit of Single-Agent Carboplatin in Vulnerable, Elderly Patients With Ovarian Cancer
The EWOC-1 trial looked at single-agent carboplatin in vulnerable, elderly patients with stage III/IV epithelial ovarian cancer vs weekly or every 3 weeks carboplatin/paclitaxel. (Source: CancerNetwork)
Source: CancerNetwork - June 5, 2019 Category: Cancer & Oncology Authors: Leah Lawrence Source Type: news
New study explains how inflammation causes gastric cancer
(Kanazawa University) Researchers from Kanazawa University and the Japan Agency for Medical Research and Development have solved the decades-old mystery of how stomach bacterium Helicobacter pylori causes gastric cancer. Using mouse models and human cancer cell lines, they showed that inflammation resulting from bacterial infection leads to the proliferation of gastric epithelial cells, which ultimately form gastric tumors. By blocking the protein pathway responsible for this proliferation, they prevented gastric tumor formation. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - April 16, 2019 Category: Biology Source Type: news
Survival Improves for Peritoneal Mesothelioma Patients in Finland
Survival time improved significantly for peritoneal mesothelioma patients in Finland who underwent a combination of surgery and chemotherapy, according to a recently released study.
The five-year survival rate was 66 percent. The median survival was 62 months.
According to a smaller, previous study in Finland, the median survival without treatment was just four months after diagnosis.
“Despite these advances in treatment…the majority of patients with malignant peritoneal mesothelioma receive only palliative care of systemic chemotherapy, leaving many eligible patients without the benefit of this more invasive treatmen...
Source: Asbestos and Mesothelioma News - April 1, 2019 Category: Environmental Health Authors: Matt Mauney Source Type: news
New study confirms EpCAM as promising target for cancer immunotherapy
(Mary Ann Liebert, Inc./Genetic Engineering News) Researchers have shown that cancer immunotherapy targeting the tumor biomarker epithelial cell adhesion molecule (EpCAM) is safe and nontoxic in mice and can significantly delay tumor formation and growth. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - March 28, 2019 Category: International Medicine & Public Health Source Type: news
SGO 2019: Pembrolizumab Combo Shows Clinical Benefit for Recurrent Epithelial Ovarian Cancer
Results of a phase II trial evaluating pembrolizumab in combination with bevacizumab and oral metronomic cyclophosphamide were presented at SGO 2019. (Source: CancerNetwork)
Source: CancerNetwork - March 19, 2019 Category: Cancer & Oncology Authors: Christina Bennett, MS Source Type: news
Study: Less-Invasive Mesothelioma Surgery Yields Better Results
A team of researchers at the Hyogo College of Medicine in Nishinomiya, Japan, studied the outcomes for pleural mesothelioma patients who received surgery at their facility between 2004 and 2016.
The results: More aggressive surgery did not help mesothelioma patients live longer.
“We showed that introducing less-invasive surgical techniques could decrease surgical risks without compromising survival,” the researchers wrote in their study, published in January in Seminars in Thoracic and Cardiovascular Surgery. “Surgery that is less invasive than conventional extrapleural pneumonectomy could achieve lower surgical ris...
Source: Asbestos and Mesothelioma News - March 14, 2019 Category: Environmental Health Authors: Matt Mauney Source Type: news
Mesothelioma Treatment Combines Proton and Photodynamic Therapy
Intraoperative photodynamic therapy combined with novel proton radiation improved survival time significantly for recent patients with advanced-stage pleural mesothelioma.
The study — the first to measure the impact of this combination — involved 10 consecutive patients treated at the University of Pennsylvania’s Abramson Cancer Center.
The treatment regimen resulted in a 90 percent, two-year disease control rate and an impressive 30.3-month median overall survival from the time of diagnosis.
All 10 patients were diagnosed before treatment began with stage 3 or stage 4 disease, which typically results in a 10 to 14-m...
Source: Asbestos and Mesothelioma News - March 12, 2019 Category: Environmental Health Authors: Matt Mauney Source Type: news
Neoadjuvant Chemotherapy in Advanced Ovarian Cancer Neoadjuvant Chemotherapy in Advanced Ovarian Cancer
Which patients with epithelial ovarian cancer should be considered for neoadjuvant chemotherapy followed by interval debulking surgery?Chinese Clinical Oncology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - February 28, 2019 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news
Chronic TGF-{beta} exposure drives stabilized EMT, tumor stemness, and cancer drug resistance with vulnerability to bitopic mTOR inhibition
Tumors comprise cancer stem cells (CSCs) and their heterogeneous progeny within a stromal microenvironment. In response to transforming growth factor–β (TGF-β), epithelial and carcinoma cells undergo a partial or complete epithelial-mesenchymal transition (EMT), which contributes to cancer progression. This process is seen as reversible because cells revert to an epithelial phenotype upon TGF-β removal. However, we found that prolonged TGF-β exposure, mimicking the state of in vivo carcinomas, promotes stable EMT in mammary epithelial and carcinoma cells, in contrast to the reversible EMT induced ...
Source: Signal Transduction Knowledge Environment - February 26, 2019 Category: Science Authors: Katsuno, Y., Meyer, D. S., Zhang, Z., Shokat, K. M., Akhurst, R. J., Miyazono, K., Derynck, R. Tags: STKE Research Articles Source Type: news
Elucidation of molecular-targeted drug resistance mechanism by lung cancer cells
(Kanazawa University) We revealed that ALK-positive lung cancer cells, treated with crizonitib, a molecular target drug, acquired resistance to the drug not only by genetic mutation but also by concomitant epithelial-to-mesenchymal transition (EMT). Further, in animal experiments, mesenchymal cancer cells due to EMT were shown to revert to epithelial ones by quisinostat, a histone deacetylase (HDAC) inhibitor; they regained sensitivity to the molecular-targeted drug. These results indicate a significant potential of overcoming resistance to molecular-targeted drugs. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - February 25, 2019 Category: Cancer & Oncology Source Type: news
